Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Treating older people with diabetes is challenging due to multiple medical comorbidities that might interfere with patients' ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Novo Nordisk ... 1 trial. The disclosure revealed that the study utilized a flexible dosing protocol and that, after 68 weeks, only 57.3% of patients on CagriSema were on the highest dose, compared to ...

Novo Nordisk closed up 4.5% Wednesday. Shares of obesity drug rival Eli Lilly, meanwhile, rose 1.4%. Speaking to CNBC ... combining semaglutide — the active ingredient in Wegovy — with amylin ...